

## Biotinylated Recombinant Human IL-17RA/IL-17R Fc Chimera Avi-tag


Catalog Number: AVI177


DESCRIPTION				
Source Human embryonic kidney cell, HEK293-derived human IL-17RA/IL-17R protein				
	Human IL-17RA/IL-17R (Leu33-Trp320) Accession # Q96F46.2	IEGRMD	Human IgG <sub>1</sub> (Pro100-Lys330)	Avi-tag
	N-terminus			C-terminus

	N-terminus	C-terminus
N-terminal Sequence Analysis	Leu33	
Structure / Form	Disulfide-linked homodimer Biotinylated via Avi-tag	
Predicted Molecular Mass	62 kDa	

SPECIFICATIONS			
SDS-PAGE	90-100 kDa, under reducing conditions.		
Activity	Measured by its binding ability in a functional ELISA.  When Recombinant human IL-17A (Catalog # 7955-IL) is immobilized at 0.500 μg/mL, 100 μL/well, Biotinylated Recombinant Human IL-17RA/IL-17R Fc Chimera Avi-tag (Catalog # AVI177) binds with an ED <sub>50</sub> of 5.00-30.0 ng/mL.		
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.		
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.		
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.		

PREPARATION AND STORAGE			
Reconstitution	Reconstitute at 250 μg/mL in PBS.		
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.  12 months from date of receipt, -20 to -70 °C as supplied.  1 month, 2 to 8 °C under sterile conditions after reconstitution.  3 months, -20 to -70 °C under sterile conditions after reconstitution.		





Rev. 8/9/2022 Page 1 of 2





## Biotinylated Recombinant Human IL-17RA/IL-17R Fc Chimera Avi-tag

Catalog Number: AVI177

## BACKGROUND

IL-17 R, also known as IL-17 RA, is a 120 kDa type I transmembrane glycoprotein protein that plays a central role in inflammatory responses (1-3). Mature human IL-17 R consists of a 288 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 525 aa cytoplasmic domain (4). The cytoplasmic domain contains a region homologous to the TIR domain of the TLR/IL-1 R family (5). Human IL-17 R shares 72% aa sequence identity with mouse and rat IL-17 R. Within the extracellular domain, it shares 18%-25% sequence identity with human IL-17 RB, C, D, and E. While the expression of IL-17 is restricted to activated T cells, IL-17 R exhibits a broad tissue distribution (4). Even in the absence of ligand, IL-17 R exists on the cell surface as a multimer (6). IL-17 R can bind IL-17 but must associate with IL-17 RC to transduce signals (7, 8). Interestingly, human IL-17 R does not appear to form productive complexes with mouse IL-17 RC (8). The IL-17 R can also signal in response to IL-17F (9). IL-17 R ligation promotes T cell activation and the production of IL-6, G-CSF, SCF, and multiple pro-inflammatory chemokines (4, 7, 9, 10). IL-17A and IL-17F synergize with TNF-α in the induction of CXCL1, G-CSF, and IL-6 (9, 11). This effect requires the presence of both TNF RI and TNF RII (9). IL-17 interactions with IL-17 R also inhibit the TNF-α induced up-regulation of fibroblast CCL5 and VCAM-1 (11). CCL5 and VCAM-1 induced effects are differentially sensitive to blockade with IL-17 R specific antibodies, suggesting that IL-17 R triggers divergent intracellular signals (11). In vivo, IL-17 R activity is important for increased generation of neutrophils and their recruitment to sites of inflammation (10, 12, 13). IL-17 R is required for host defense against microbial infection and for the progression of arthritis from inflammation to destructive joint erosion (10, 13). Our Avi-tag Biotinylated human IL-17R chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. P

## References:

- 1. Iwakura, Y. and H. Ishigame (2006) J. Clin. Invest. 116:1218.
- 2. Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
- 3. Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
- 4. Yao, Z. et al. (1995) Immunity 3:811.
- 5. Novatchkova, M. et al. (2003) Trends Biochem. Sci. 28:226.
- 6. Kramer, J.M. et al. (2006) J. Immunol. 176:711.
- 7. Hymowitz, S.G. et al. (2001) EMBO J. 20:5332.
- 8. Toy, D. et al. (2006) J. Immunol. 177:36.
- 9. McAllister, F. et al. (2005) J. Immunol. 175:404.
- 10. Ye, P. et al. (2001) J. Exp. Med. 194:519.
- 11. Schnyder, B. et al. (2005) Cytokine 31:191.
- 12. Tan, W. et al. (2006) J. Immunol. 176:6186.
- 13. Lubberts, E. et al. (2005) J. Immunol. 175:3360.